Status:

TERMINATED

Velphoro and Impact on the Oral Cavity and Gut Microbiome

Lead Sponsor:

RWTH Aachen University

Conditions:

Hyperphosphatemia

Eligibility:

All Genders

18+ years

Brief Summary

This pilot study will be carried out to determine if the regular intake of iron-based Velphoro® by hyperphosphatemia patients influences the microbiome in the oral cavity and/or the gut.

Detailed Description

The aim of this study is to investigate potential changes in the microbiome of the oral cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one month. The principal int...

Eligibility Criteria

Inclusion

  • Suffering from hyperphosphatemia
  • Current treatment with a stable dose of a non-iron containing phosphate binder,
  • No or only parenteral iron application
  • Age of ≥ 18 years
  • Written informed consent prior to study participation
  • The subject is willing and able to follow the procedures outlined in the protocol
  • Control group:
  • Normal renal function
  • No hyperphosphatemia
  • Age- and sex-matched and oral disease status-matched (dental caries and periodontal disease) in comparison to the hyperphosphatemia group
  • Written informed consent prior to study participation
  • The subject is willing and able to follow the procedures outlined in the protocol

Exclusion

  • Age less than 18 years
  • Currently on oral iron application
  • Antibiotic treatment within the last two months
  • Severe medical events within the last three months
  • Planned surgery for the duration of the sampling
  • Acute/chronic gastrointestinal infections
  • Smokers
  • Oral candidiasis
  • Oral cancer
  • Pregnant and lactating females
  • Haemochromatosis history
  • Committed to an institution by legal or regulatory order
  • Participation in a parallel interventional clinical trial
  • Receipt of an investigational drug within 30 days prior to inclusion into this study
  • The subject is mentally or legally incapacitated
  • Only for the patient group:
  • Never got any phosphate binder
  • Allergy to Velphoro®
  • Celiac disease or any other chronic inflammatory bowel disease
  • Previous major surgery in the gastrointestinal tract

Key Trial Info

Start Date :

February 28 2018

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

October 6 2020

Estimated Enrollment :

22 Patients enrolled

Trial Details

Trial ID

NCT03409757

Start Date

February 28 2018

End Date

October 6 2020

Last Update

November 25 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospital of RWTH Aachen, Department of Medicine II

Aachen, Germany